| pubmed-article:17032895 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17032895 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:17032895 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:17032895 | lifeskim:mentions | umls-concept:C0598934 | lld:lifeskim |
| pubmed-article:17032895 | lifeskim:mentions | umls-concept:C0549178 | lld:lifeskim |
| pubmed-article:17032895 | pubmed:issue | 36 | lld:pubmed |
| pubmed-article:17032895 | pubmed:dateCreated | 2006-10-11 | lld:pubmed |
| pubmed-article:17032895 | pubmed:abstractText | The MISCAN-Fadia model was used to analyze the impact of screening and adjuvant treatment on U.S. breast cancer mortality between 1975 and 2000. MISCAN-Fadia uses the concept of "fatal diameter" to model survival and screening benefit and is based on continuous tumor growth. It consists of four major components: population, natural history, screening, and treatment. Population parameters were quantified using U.S. population data. Most natural history and screening parameters were fitted to the Swedish Two County screening trial data; some were based on Surveillance, Epidemiology, and End Results data. Adjuvant treatment parameters were quantified using data from the Early Breast Cancer Trialists' Collaborative Group's meta-analysis. The simulated trend in incidence matches the observed trend reasonably well; the simulated mortality is equal to the observed in 1975 but becomes increasingly too high in 2000. We estimate that screening leads to a 15% and adjuvant treatment to a 21% mortality reduction in the year 2000. | lld:pubmed |
| pubmed-article:17032895 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17032895 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17032895 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17032895 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17032895 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17032895 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17032895 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17032895 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17032895 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17032895 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17032895 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17032895 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17032895 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17032895 | pubmed:issn | 1052-6773 | lld:pubmed |
| pubmed-article:17032895 | pubmed:author | pubmed-author:de... | lld:pubmed |
| pubmed-article:17032895 | pubmed:author | pubmed-author:HabbemaJ... | lld:pubmed |
| pubmed-article:17032895 | pubmed:author | pubmed-author:van... | lld:pubmed |
| pubmed-article:17032895 | pubmed:author | pubmed-author:BoerRobR | lld:pubmed |
| pubmed-article:17032895 | pubmed:author | pubmed-author:TanSita Y G... | lld:pubmed |
| pubmed-article:17032895 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17032895 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17032895 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17032895 | pubmed:pagination | 56-65 | lld:pubmed |
| pubmed-article:17032895 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:17032895 | pubmed:meshHeading | pubmed-meshheading:17032895... | lld:pubmed |
| pubmed-article:17032895 | pubmed:meshHeading | pubmed-meshheading:17032895... | lld:pubmed |
| pubmed-article:17032895 | pubmed:meshHeading | pubmed-meshheading:17032895... | lld:pubmed |
| pubmed-article:17032895 | pubmed:meshHeading | pubmed-meshheading:17032895... | lld:pubmed |
| pubmed-article:17032895 | pubmed:meshHeading | pubmed-meshheading:17032895... | lld:pubmed |
| pubmed-article:17032895 | pubmed:meshHeading | pubmed-meshheading:17032895... | lld:pubmed |
| pubmed-article:17032895 | pubmed:meshHeading | pubmed-meshheading:17032895... | lld:pubmed |
| pubmed-article:17032895 | pubmed:meshHeading | pubmed-meshheading:17032895... | lld:pubmed |
| pubmed-article:17032895 | pubmed:meshHeading | pubmed-meshheading:17032895... | lld:pubmed |
| pubmed-article:17032895 | pubmed:meshHeading | pubmed-meshheading:17032895... | lld:pubmed |
| pubmed-article:17032895 | pubmed:meshHeading | pubmed-meshheading:17032895... | lld:pubmed |
| pubmed-article:17032895 | pubmed:meshHeading | pubmed-meshheading:17032895... | lld:pubmed |
| pubmed-article:17032895 | pubmed:meshHeading | pubmed-meshheading:17032895... | lld:pubmed |
| pubmed-article:17032895 | pubmed:meshHeading | pubmed-meshheading:17032895... | lld:pubmed |
| pubmed-article:17032895 | pubmed:meshHeading | pubmed-meshheading:17032895... | lld:pubmed |
| pubmed-article:17032895 | pubmed:meshHeading | pubmed-meshheading:17032895... | lld:pubmed |
| pubmed-article:17032895 | pubmed:meshHeading | pubmed-meshheading:17032895... | lld:pubmed |
| pubmed-article:17032895 | pubmed:meshHeading | pubmed-meshheading:17032895... | lld:pubmed |
| pubmed-article:17032895 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:17032895 | pubmed:articleTitle | The MISCAN-Fadia continuous tumor growth model for breast cancer. | lld:pubmed |
| pubmed-article:17032895 | pubmed:affiliation | Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. | lld:pubmed |
| pubmed-article:17032895 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17032895 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:17032895 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17032895 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17032895 | lld:pubmed |
